The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.
Due to current health and safety precautions, hard copy mailing of IMF publications are temporarily delayed up to several weeks. However, digital versions of all IMF publications are available below.
September 27, 2018
This publication discusses the use of Revlimid (lenalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
April 13, 2020
The Understanding SARCLISA® (isatuximab-irfc) booklet discusses a novel anti-CD38 monoclonal antibody that is approved for patients with relapsed and…
July 31, 2018
This publication discusses the use of Thalomid (Thalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
May 18, 2018
This publication discusses the effects of myeloma on the immune system.
September 20, 2019
The Understanding the VRd Regimen booklet discusses a combination therapy for treating newly diagnosed myeloma that consists of three drugs
We Thank Our Sponsors:
Amgen, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Karyopharm, Sanofi, and Takeda Oncology